Gaza Strip struggles to address burgeoning opioid crisis

Years of blockades, conflict, and mass unemployment have fueled an underground illicit drug industry that is now spilling out as an opioid crisis in Gaza Strip. Treatment facilities say they lack the resources to properly help those wanting to be free of addictions. 

|
Adel Hana/AP
Hamas security forces prepare to burn bars of hashish and boxes of Tramadol in Gaza City on Oct. 22, 2018. In the face of mass unemployment and the ongoing conflict with Israel, an opioid crisis has quietly spread across the Gaza Strip.

An opioid crisis has quietly spread in the Gaza Strip, trapping thousands in the cycles of addiction and adding another layer of misery to the blockaded and impoverished coastal territory.

The scourge can be traced to the mass import of cheap opioid-based Tramadol pain pills through smuggling tunnels under Gaza's border more than a decade ago. A more addictive black-market form of the drug called Tramal has since taken hold.

"I have seen the top elites taking it – university students, girls, and respectful people," said Dr. Fadel Ashour, who treats addicts in his dimly lit clinic.

There are no reliable estimates for the number of addicts in Gaza, a conservative society of 2 million where it is considered shameful to admit to such a problem. A 2017 study by the World Health Organization estimated that 10,047 males over the age of 15 were "high-risk drug users."

Dr. Ashour, a psychiatrist, neurologist and professor at Gaza's al-Azhar University, believes the number is much higher.

Prices have shot up in recent years as a result of tunnel closures and an anti-drug campaign by the ruling Islamic militant group Hamas. Yet for the vast majority of sufferers, rehab isn't available for those who can no longer finance the habit.

Israel and Egypt imposed a blockade on Gaza after Hamas took over in 2007. Ostensibly meant to prevent arms from reaching Hamas, the blockade made it all but impossible for people to move in and out of Gaza and devastated the economy. As conditions worsened, a thriving smuggling industry along the Egyptian border pumped in a cheap supply of Tramadol, an addictive painkiller that found a welcome market among the masses of idle youths.

Tramadol, a synthetic opioid analgesic, is considered a controlled substance by the United States Food and Drug Administration, in the same category as well-known medications like Valium and Xanax.

The WHO study cited the blockade, high unemployment among university graduates, and never-ending conflict with Israel as factors associated with "widespread" Tramadol abuse.

It said users turned to the drug to "escape problems," obtain a "feeling of relaxation," to "not think," and to fall asleep.

Tramal, believed to be a more addictive black market form of Tramadol, arrived later, gaining popularity after the first war between Hamas and Israel in 2009.

Tramal was cheap, less than 50 cents a tablet, and people discovered its sedative effects at a time when they were "trying to overcome their anxiety because Gaza was a very traumatic environment," said Ashour.

Experts in Gaza say the drug is illegally manufactured in India and has higher amounts of opioid and possibly hashish and toxic substances. The illicit pills are also much more addictive.

Dr. Elyad Davidson, head of the pain relief unit at Israel's Hadassah Medical Center, said both drugs in Gaza are variants of the medication known generically as tramadex – a type of opioid typically prescribed as a painkiller, but which also increases levels of serotonin, like antidepressants.

While tramadex is not as potent as morphine, "there is no doubt that it is addictive," Dr. Davidson said.

Some countries don't view it "really as an opioid," which he called a "mistake" that can lead to wider use and addiction.

He said patients who become accustomed to high doses experience painful withdrawal symptoms.

Abu Karim, a 29-year-old Palestinian father of five, said he began taking Tramal five years ago after a friend told him it would help him smoke his water pipe, or shisha, without coughing. He declined to give his full name because of the stigma surrounding addiction.

"I liked it, so I began taking it for shisha, then to relax," said Abu Karim, a thin, pale figure wearing a sports hoodie with matching pants.

But in recent months, prices have shot up. A single pill can cost about $20, well beyond most people's means.

Today, he's among the few patients at the Hope Center, the first and only rehab facility in Gaza. Since opening at Gaza's only psychiatric hospital in 2017, it has treated 230 people, 90 percent of them tramadex users.

Patients are admitted willingly, but the center has nowhere near the capacity to treat the vast number of addicts. Doctors say they need a national center with more facilities.

In the meantime, Hamas' anti-drug police are cracking down on supplies. "Tramal smuggling has become a national security issue," said police spokesman Ayman Batniji.

The Health Ministry has curtailed Tramadol imports and banned four kinds of over-the-counter drugs, including Lyrica. Police have seized hundreds of thousands of pills.

Nearly a year of border protests against the Israeli blockade have added a new element to the crisis. Hundreds of young men have been shot by the Israeli army, which says it is defending its border.

Mahmoud, a 29-year-old, said he became addicted to Lyrica after he was shot during a protest. Unemployed and unmarried, he is now being treated by Dr. Ashour.

"I don't want to reach a level in which I lose my personality and dignity because of the drugs," said Mahmoud, who would not give his family name because of the social stigma associated with addiction. "I want to stop."

This story was reported by The Associated Press.

You've read  of  free articles. Subscribe to continue.
Real news can be honest, hopeful, credible, constructive.
What is the Monitor difference? Tackling the tough headlines – with humanity. Listening to sources – with respect. Seeing the story that others are missing by reporting what so often gets overlooked: the values that connect us. That’s Monitor reporting – news that changes how you see the world.

Dear Reader,

About a year ago, I happened upon this statement about the Monitor in the Harvard Business Review – under the charming heading of “do things that don’t interest you”:

“Many things that end up” being meaningful, writes social scientist Joseph Grenny, “have come from conference workshops, articles, or online videos that began as a chore and ended with an insight. My work in Kenya, for example, was heavily influenced by a Christian Science Monitor article I had forced myself to read 10 years earlier. Sometimes, we call things ‘boring’ simply because they lie outside the box we are currently in.”

If you were to come up with a punchline to a joke about the Monitor, that would probably be it. We’re seen as being global, fair, insightful, and perhaps a bit too earnest. We’re the bran muffin of journalism.

But you know what? We change lives. And I’m going to argue that we change lives precisely because we force open that too-small box that most human beings think they live in.

The Monitor is a peculiar little publication that’s hard for the world to figure out. We’re run by a church, but we’re not only for church members and we’re not about converting people. We’re known as being fair even as the world becomes as polarized as at any time since the newspaper’s founding in 1908.

We have a mission beyond circulation, we want to bridge divides. We’re about kicking down the door of thought everywhere and saying, “You are bigger and more capable than you realize. And we can prove it.”

If you’re looking for bran muffin journalism, you can subscribe to the Monitor for $15. You’ll get the Monitor Weekly magazine, the Monitor Daily email, and unlimited access to CSMonitor.com.

QR Code to Gaza Strip struggles to address burgeoning opioid crisis
Read this article in
https://www.csmonitor.com/World/Middle-East/2019/0226/Gaza-Strip-struggles-to-address-burgeoning-opioid-crisis
QR Code to Subscription page
Start your subscription today
https://www.csmonitor.com/subscribe